Browsing Genetics and Epidemiology by author "Kaiser, Martin"
Now showing items 21-40 of 40
-
Impact of mitochondrial DNA mutations in multiple myeloma.
Hoang, PH; Cornish, AJ; Chubb, D; Jackson, G; Kaiser, M; et al. (NATURE PUBLISHING GROUP, 2020-05-01) -
Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients.
Panopoulou, A; Easdale, S; Ethell, M; Nicholson, E; Potter, M; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2023-02-01)Refined prediction of early relapse following standard-of-care (SoC) autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) could inform real-world risk-stratified post-ASCT strategies. We ... -
Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma.
Rata, M; Blackledge, M; Scurr, E; Winfield, J; Koh, D-M; et al. (SPRINGER, 2022-07-28)BACKGROUND: Whole-body (WB) MRI, which includes diffusion-weighted imaging (DWI) and T1-w Dixon, permits sensitive detection of marrow disease in addition to qualitative and quantitative measurements of disease and response ... -
Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.
Auner, HW; Brown, SR; Walker, K; Kendall, J; Dawkins, B; et al. (SPRINGERNATURE, 2022-04-01)The all-oral combination of ixazomib, cyclophosphamide, and dexamethasone (ICD) is well tolerated and effective in newly diagnosed and relapsed multiple myeloma (MM). We carried out MUKeight, a randomised, controlled, open, ... -
MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma.
Kendall, J; Hall, A; Roberts, S; Brown, S; Boyd, K; et al. (BMJ PUBLISHING GROUP, 2022-10-26)INTRODUCTION: Multiple myeloma is a malignancy of plasma cells with around 6000 new cases per year in the UK. Cyclophosphamide plus prednisolone is considered a standard of care for disease and symptom control in the ... -
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.
Li, N; Johnson, DC; Weinhold, N; Studd, JB; Orlando, G; et al. (NATURE PUBLISHING GROUP, 2016-11-24)Genome-wide association studies have identified several risk loci for multiple myeloma (MM); however, the mechanisms by which they influence MM are unknown. Here by using genetic association data and functional characterization, ... -
Mutational processes contributing to the development of multiple myeloma.
Hoang, PH; Cornish, AJ; Dobbins, SE; Kaiser, M; Houlston, RS (NATURE PUBLISHING GROUP, 2019-08-06)To gain insight into multiple myeloma (MM) tumorigenesis, we analyzed the mutational signatures in 874 whole-exome and 850 whole-genome data from the CoMMpass Study. We identified that coding and non-coding regions are ... -
Neutral tumor evolution in myeloma is associated with poor prognosis.
Johnson, DC; Lenive, O; Mitchell, J; Jackson, G; Owen, R; et al. (AMER SOC HEMATOLOGY, 2017-10-05)Recent studies suggest that the evolutionary history of a cancer is important in forecasting clinical outlook. To gain insight into the clonal dynamics of multiple myeloma (MM) and its possible influence on patient outcomes, ... -
Phenome-wide Mendelian randomisation analysis of 378,142 cases reveals risk factors for eight common cancers.
Went, M; Sud, A; Mills, C; Hyde, A; Culliford, R; et al. (Springer Science and Business Media LLC, 2024-03-25)For many cancers there are only a few well-established risk factors. Here, we use summary data from genome-wide association studies (GWAS) in a Mendelian randomisation (MR) phenome-wide association study (PheWAS) to identify ... -
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.
Shah, V; Sherborne, AL; Johnson, DC; Ellis, S; Price, A; et al. (SPRINGERNATURE, 2020-03-11) -
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
Shah, V; Sherborne, AL; Walker, BA; Johnson, DC; Boyle, EM; et al. (NATURE PUBLISHING GROUP, 2018-01-01)Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent genetic aberrations is required as outcomes are variable despite apparent similar staging. We assayed copy number alterations (CNA) ... -
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
Fernández de Larrea, C; Kyle, R; Rosiñol, L; Paiva, B; Engelhardt, M; et al. (SPRINGERNATURE, 2021-12-02)Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. ... -
Regions of homozygosity as risk factors for multiple myeloma.
Went, M; Sud, A; Li, N; Johnson, DC; Mitchell, JS; et al. (WILEY, 2019-07-01)Genomic regions of homozygosity (ROH), detectable in outbred populations, have been implicated as determinants of inherited risk. To examine whether ROH is associated with risk of multiple myeloma (MM), we performed ... -
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.
Bird, S; Panopoulou, A; Shea, RL; Tsui, M; Saso, R; et al. (ELSEVIER SCI LTD, 2021-05-25) -
Search for multiple myeloma risk factors using Mendelian randomization.
Went, M; Cornish, AJ; Law, PJ; Kinnersley, B; van Duin, M; et al. (AMER SOC HEMATOLOGY, 2020-05-26)The etiology of multiple myeloma (MM) is poorly understood. Summary data from genome-wide association studies (GWASs) of multiple phenotypes can be exploited in a Mendelian randomization (MR) phenome-wide association study ... -
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino, M; Cairns, DA; Lahuerta, JJ; Wester, R; Bertsch, U; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-10-10)PURPOSE: Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the ... -
Subclonal TP53 copy number is associated with prognosis in multiple myeloma.
Shah, V; Johnson, DC; Sherborne, AL; Ellis, S; Aldridge, FM; et al. (AMER SOC HEMATOLOGY, 2018-12-06)Multiple myeloma (MM) is a genetically heterogeneous cancer of bone marrow plasma cells with variable outcome. To assess the prognostic relevance of clonal heterogeneity of TP53 copy number, we profiled tumors from 1777 ... -
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.
Went, M; Kinnersley, B; Sud, A; Johnson, DC; Weinhold, N; et al. (BMC, 2019-08-20)BACKGROUND: While genome-wide association studies (GWAS) of multiple myeloma (MM) have identified variants at 23 regions influencing risk, the genes underlying these associations are largely unknown. To identify candidate ... -
Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms.
Hoang, PH; Dobbins, SE; Cornish, AJ; Chubb, D; Law, PJ; et al. (2018-11)Multiple myeloma (MM) is a biologically heterogeneous malignancy, however, the mechanisms underlying this complexity are incompletely understood. We report an analysis of the whole-genome sequencing of 765 MM patients from ... -
Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms.
Hoang, PH; Dobbins, SE; Cornish, AJ; Chubb, D; Law, PJ; et al. (NATURE PUBLISHING GROUP, 2018-11-01)Multiple myeloma (MM) is a biologically heterogeneous malignancy, however, the mechanisms underlying this complexity are incompletely understood. We report an analysis of the whole-genome sequencing of 765 MM patients from ...